Adjusted EBITDA rose 78% yr/yr, beating analyst expectations
Analyst coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"
Wall Street's median 12-month price target for AtriCure Inc is $50.00, about 49.2% above its July 22 closing price of $33.52
The stock recently traded at 157 times the next 12-month earnings vs. a P/E of 231 three months ago
Result drivers and key details
Pain management growth - Sales of cryoSPHERE MAX probe for post-operative pain management drove U.S. revenue growth
ATRC•
